Floatz logo

Infigratinib

PR-Positive Breast Cancer

Jennifer Lee Caswell-JinSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the PR-Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Jennifer Lee Caswell-Jin
Phase 2BB
Letrozole
Ruth O'Regan
Phase 2BB
Cyclophosphamide
University of Washington
Phase 2B
FILGRASTIM
University of Washington
Phase 2B
Palbociclib
Abramson Cancer Center at Penn Medicine
Phase 2B

View all 37 →

Same molecule, other indications

Infigratinib is also rated in:

GBMDormant
CCC
Indicative ·
54 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →